Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If Gerald and company did a reverse split now, the stock would implode just like AMBS and be delisted in short order. JMHO.
Same old song..."news coming" and "we are planning" this and that... all talk, more and more dilution with dubious plans or purpose or focus...blah blah blah... sp is pitiful... Where is the BOD?
Not happy about the continued dilution (85M) but okay with it as long as it is being used to meet some milestones towards commercialization of Videssa or Lympro or phase 3 Tollovir. I wish GC would elaborate more on progress on above. Just my humble opinion.
The annual report will tell all when it comes out. If revenue up and cost down, the stock goes up. If revenue down and costs up then stock goes into the toilet. The rest is all speculation. The above is just my humble opinion. Annual report should provide more information on trajectory of Lympro and Videssa. Fingers crossed on good report.
Does anyone know when the annual report is due out? Numbers speak louder than words. It would be good to see revenues up and expenses down. Lots of talk about " we are planning." We need more talk about "we are doing." Company has so much potential. Sad to see the stock price floundering. The above is just my humble opinion.
AMBS trending up. Would be good to get some news.
Would be interesting to hear more about the policies issues holding up Lympro and more information of when they might be resolved.
Lympro would pair nicely with new drug in clinical trials, Lecanemab. Lecanemab showing 27% reduction in cognitive decline.
So Todos out of stock at Walmart. Tollo19 still selling on Amazon and no Tollovid on China's largest online marketplace Allibaba. Way to go Todos Marketing group!
Gerald should be on a plane to China now to sell thousands of bottles of Tollovid.
What a need and opportunity.
Is Tollovid on Allibaba? If not it should be.
Time to partner or sell this company to a firm that has the means and leadership to develop its potential. That would be a boon to shareholders. JMHO.
Just like with AMBS Gerald has too many horses in the race and too little hay and oats to feed them on this pharm. Perhaps have been better tactics for small start up to focus on a couple items like Videssa, Lympro, and Tollovir rather than take on too many projects without the ability to fund adequately. No attempt to secure grants? Don't understand inability or unwillingness to partner? Marketing has been poor. What happened to securing Israel EUA? Here we are almost a year later down from .08 to .01 with a drug that could cure Covid-19. Asset like Dr Arad underutilized. That flag football stunt was ridiculous waste of time and resources. If it's true, terrible to hear lab techs not being paid. Where is BOD?
On the plus side, getting Tollovid for sale on Walmart was good. That should help sales. Testing should produce more revenue. Loss down this last quarterly report. Tollivid probably best hope for Long Covid. Bunch of really smart investors commenting on this board regularly.
Gerald tends to sugarcoat and deflect and delay, which most investors can see right through. Better for Gerald to underpromise and overperform. He hasn't learned that lesson yet.
We need some kind of breakthrough here. Big partner, EUA Tollovir, etc. Above just my humble opinion.
Happy Thanksgiving to all!
Would be great if there was some good news like a ready willing and able partner to move some of the projects forward... Elto, MANF, Engineered Skin Cell... So much potential. We can only speculate at this point. Hoping for some news this week.
Hey Freegriff. What's your read on the recent uptick in SP here?
Anyone know what is behind the breakout?
Perhaps AMBS SP bump a leading indicator of success brewing at Todos. Pure speculation of course, IMHO.
Nice to see 10-Q out on time.
Wow. That is great news that Tollovid now on sale at Walmart! Need to now get Tolloviid in CVS.
Would like to hear more case studies of folks with long covid being healed with Tolovid, especially after Paxlovid failure.
Up nicely today on over 4M shares volume.
When is 3rd quarter report due out?
I pray they don't try to uplist at these levels. It would just be another disaster like AMBS. Just my humble opinion.
I hope they don't r/s this stock and upllist before stock gains some strength. In my humble opinion it would just be another ambs. Flipper would short the sh@t out of the stock and we would be right back at these levels in a couple of weeks. Past is prologue.... The above, of course, is my humble opinion.
Yup. Tollovid, best kept secret in America. I wish our marketing group was more adept. Couple of runs of an ad on Fox would help...but what do I know? Above is just my humble opinion. I hope we get some news soon. Not much happened here in a while and the stock is languishing...
Thanks for posting Sloan!
Well put Les. What about that update on the European excursion we were supposed to get after Passover? Be nice to get an update on progress on Tollovid as an OTC medication. We have the right drug at the right time and our leadership seem unable to capitalize on it. Where is the marketing group? Very frustrating. Above is just my humble opinion.
Nothing out of the company about the great European trek.
Les, I really appreciated the straight forward plan from Don about how he was going to rebuild the company, including partnerships. Gave me hope that AMBS will emerge out of the morass it's been in for some time. Go AMBS!
News out! First PR from AMBS in quite a while. Plan for AMBS re-emergence.
https://www.otcmarkets.com/stock/AMBS/news/Amarantus-Signs-Non-Binding-Term-Sheet-to-Divest-Cutanogen-Corporation-in-Exchange-for-the-Extinguishment-of-Potential-2?id=354075
Gerald often talked about early investors getting rewarded. RS and deathspiral following would not exactly be rewarding early investors. IMHO.
I thought that 3CL Pharma was supposed to raise capital as a separate entity and not continue to bleed Todos.
Outstanding shares now. 1,193,175,121 as of 4/22/22.
As AMBS shareholders, I think we are entitled to a business plan outlining objectives towards commercialization of ELTO and MANF. It would be nice to get an update from Don on his strategy. It was a good start to get the annual report and see things moving again but as a shareholder I would like to know what direction they will be going in... I hope the history of over-promising and under-delivering is over. A thoughtful and plan-ful approach would be appreciated with measured and realistic updates.
So with the financials due by tomorrow, the 13D should have been posted today. I have not seen it yet. Does that mean the 13D coming at the same time or the financials will be late?
I guess I dont get why Todos marketing folks didnt put ads on Fox or News Max. That would have been my first stab at getting more name recognition to an audience likely to purchase Tollovid. That silly flag football stunt was a waste of time and money. The above is just my humble opinion.
Todos ran two studies this year testing the efficacy of Tollovir, purchased Provista Diagnostics and 3CL Pharma. Launched sale of novel theraputic nutraceutical which appears to be a safer and more efficacious than Pfizer, Merck's or Gilead's antivirals.
Had sales of $12M. Many upstart BP have huge burn rates with no sales for years before they get their drug to market. Moved Videssa and Lympro towards commercialization. All in all a pretty good year, with what sounds like robust sales in the 1st quarter of 2022. In my humble opinion the stock price will recover when others see the value of this company and its pipeline of products. Hoping for EUAs for Tollovir in Greece and Israel and partner to take Tollovir though Phase 2/3 and beyond. JMHO.
I agree. Phase 2 Tollovir excellent results. Closing on 3CL Pharma excellent. Videssa moving forward. Excellent. However, the market is not responding and Gerald and company have continued to dilute the stock with 140M shares in last couple months. Not much attempt on the part of CEO to support the share price. You would think with that crack leadership team we could do better than .02+ a share and dropping. I find it all quite unbelievable given the above milestones and reports of excellent earnings. This stock should be at least .50 cents (shaking head in disbelief). This is just my humble opinion.
Wow. 140M shares diluted in the last couple months! Gerald talks about us early investors being rewarded. Not so far. It's my hope Todos just sells 3CL Pharma to a large BP and uses the proceeds to do a huge stock buyback and to fund the current product pipeline. This continuous dilution is eroding the stock price and stockholders investment. It's also making any uplist in the near term less likely. Just venting. The above is just my opinion.